LifeMine Announces First Participant Dosed in First-in-human Phase 1 Clinical Trial of LIFE-001, Designed De Novo to Become a Field Dominating Immunosuppressive for Immune-mediated Disorders and Transplantation

LifeMine Therapeutics Appoints Jennifer A. Jarrett to Board of Directors

Fierce Biotech names LifeMine Therapeutics as one of its “Fierce 15” Biotech Companies of 2022

LifeMine Therapeutics Announces $175 Million Series C Financing